Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Azaepothilone B; BMS-247550; Epothilone B analogue; Ixempra; NSC 710428; Patupilone analogue

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GBF
  • Developer Bristol-Myers Squibb; R-Pharm; Yale University
  • Class Antineoplastics; Epothilones; Macrolides; Small molecules
  • Mechanism of Action Cell cycle inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase II Ovarian cancer
  • No development reported Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer
  • Discontinued Cancer; Endometrial cancer; Prostate cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 03 Apr 2017 Phase-II clinical trials in Ovarian cancer (In the elderly, Metastatic disease, Second-line therapy or greater, In adults, Combination therapy) in USA (IV) (NCT03093155)
  • 03 Apr 2017 Phase-II clinical trials in Ovarian cancer (Monotherapy, Metastatic disease, Second-line therapy or greater, In adults, In the elderly) in USA (IV) (NCT03093155)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top